{"id":"https://openalex.org/W2284518511","doi":"https://doi.org/10.18632/oncotarget.7043","title":"Mechanisms of resistance and sensitivity to anti-HER2 therapies in HER2+ breast cancer","display_name":"Mechanisms of resistance and sensitivity to anti-HER2 therapies in HER2+ breast cancer","publication_year":2016,"publication_date":"2016-01-27","ids":{"openalex":"https://openalex.org/W2284518511","doi":"https://doi.org/10.18632/oncotarget.7043","mag":"2284518511","pmid":"https://pubmed.ncbi.nlm.nih.gov/26824988","pmcid":"https://www.ncbi.nlm.nih.gov/pmc/articles/5325455"},"language":"en","primary_location":{"id":"doi:10.18632/oncotarget.7043","doi":"https://doi.org/10.18632/oncotarget.7043","is_oa":true,"landing_page_url":"https://doi.org/10.18632/oncotarget.7043","pdf_url":"http://www.oncotarget.com/index.php?journal=oncotarget&page=article&op=download&path%5B%5D=7043&path%5B%5D=20010","source":{"id":"https://openalex.org/S126644158","display_name":"Oncotarget","issn_l":"1949-2553","issn":["1949-2553"],"is_oa":true,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","medline","poland-100","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310316297","host_organization_name":"Impact Journals LLC","host_organization_lineage":["https://openalex.org/P4310316297"],"host_organization_lineage_names":["Impact Journals LLC"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Oncotarget","raw_type":"journal-article"},"volume":null,"type":"review","indexed_in":["crossref","pubmed"],"open_access":{"is_oa":true,"oa_status":"diamond","oa_url":"http://www.oncotarget.com/index.php?journal=oncotarget&page=article&op=download&path%5B%5D=7043&path%5B%5D=20010","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5064252296","display_name":"D\u00e9bora De Melo Gagliato","orcid":"https://orcid.org/0000-0001-7480-0674","observed_orcids":["https://orcid.org/0000-0001-7480-0674"]},"institutions":[{"id":"https://openalex.org/I4210137585","display_name":"Instituto de Oncologia do Paran\u00e1","ror":"https://ror.org/04xg96b46","country_code":"BR","type":"facility","lineage":["https://openalex.org/I4210137585"]}],"countries":["BR"],"is_corresponding":false,"raw_author_name":"Debora de Melo Gagliato","raw_affiliation_strings":["Centro de Oncologia do Paran\u00e1, Curitiba SP, Brazil"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Centro de Oncologia do Paran\u00e1, Curitiba SP, Brazil","institution_ids":["https://openalex.org/I4210137585"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5021572863","display_name":"Denis L. Fontes Jardim","orcid":"https://orcid.org/0000-0003-4663-1521","observed_orcids":["https://orcid.org/0000-0003-4663-1521"]},"institutions":[{"id":"https://openalex.org/I4210137585","display_name":"Instituto de Oncologia do Paran\u00e1","ror":"https://ror.org/04xg96b46","country_code":"BR","type":"facility","lineage":["https://openalex.org/I4210137585"]}],"countries":["BR"],"is_corresponding":false,"raw_author_name":"Denis Leonardo Fontes Jardim","raw_affiliation_strings":["Centro de Oncologia do Paran\u00e1, Curitiba SP, Brazil"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Centro de Oncologia do Paran\u00e1, Curitiba SP, Brazil","institution_ids":["https://openalex.org/I4210137585"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5076259914","display_name":"Mario Marchesi","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I118019719","display_name":"F. Hoffmann-La Roche AG","ror":"https://ror.org/00by1q217","country_code":"CH","type":"company","lineage":["https://openalex.org/I118019719"]}],"countries":["CH"],"is_corresponding":false,"raw_author_name":"Mario Sergio Pereira Marchesi","raw_affiliation_strings":["Roche Pharmaceuticals, S\u00e3o Paulo SP, Brazil"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Roche Pharmaceuticals, S\u00e3o Paulo SP, Brazil","institution_ids":["https://openalex.org/I118019719"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5018617106","display_name":"Gabriel N. Hortob\u00e1gyi","orcid":"https://orcid.org/0000-0002-4873-4412","observed_orcids":["https://orcid.org/0000-0002-4873-4412"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Gabriel N. Hortobagyi","raw_affiliation_strings":["The University of Texas MD Anderson Cancer Center, Houston, TX, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"The University of Texas MD Anderson Cancer Center, Houston, TX, USA","institution_ids":["https://openalex.org/I1343551460"]}]}],"institutions":[],"countries_distinct_count":3,"institutions_distinct_count":3,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":2.745,"has_fulltext":true,"cited_by_count":198,"citation_normalized_percentile":{"value":0.94690265,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":98,"max":100},"biblio":{"volume":"7","issue":"39","first_page":"64431","last_page":"64446"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10755","display_name":"HER2/EGFR in Cancer Research","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10755","display_name":"HER2/EGFR in Cancer Research","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10417","display_name":"Lung Cancer Treatments and Mutations","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10696","display_name":"Gastric Cancer Management and Outcomes","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/her2-targeted-therapy","display_name":"HER2-targeted therapy","score":0.8320000171661377},{"id":"https://openalex.org/keywords/trastuzumab","display_name":"trastuzumab","score":0.9089999794960022},{"id":"https://openalex.org/keywords/drug-resistance-mechanisms","display_name":"drug resistance mechanisms","score":0.7400000095367432},{"id":"https://openalex.org/keywords/trastuzumab-resistance","display_name":"trastuzumab resistance","score":0.8199999928474426},{"id":"https://openalex.org/keywords/trastuzumab-emtansine","display_name":"trastuzumab emtansine","score":0.8259999752044678},{"id":"https://openalex.org/keywords/pertuzumab","display_name":"pertuzumab","score":0.8339999914169312},{"id":"https://openalex.org/keywords/her2-overexpression","display_name":"HER2 overexpression","score":0.5329999923706055},{"id":"https://openalex.org/keywords/her2-amplification","display_name":"HER2 amplification","score":0.5659999847412109},{"id":"https://openalex.org/keywords/tyrosine-kinase-inhibitors","display_name":"tyrosine kinase inhibitors","score":0.7839999794960022},{"id":"https://openalex.org/keywords/her2-negative-breast-cancer","display_name":"HER2-negative breast cancer","score":0.31700000166893005}],"concepts":[{"id":"https://openalex.org/C2781164504","wikidata":"https://www.wikidata.org/wiki/Q1998021","display_name":"Pertuzumab","level":5,"score":0.7187469005584717},{"id":"https://openalex.org/C2779786085","wikidata":"https://www.wikidata.org/wiki/Q412616","display_name":"Trastuzumab","level":4,"score":0.716915488243103},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.6629189848899841},{"id":"https://openalex.org/C530470458","wikidata":"https://www.wikidata.org/wiki/Q128581","display_name":"Breast cancer","level":3,"score":0.64697265625},{"id":"https://openalex.org/C2779438470","wikidata":"https://www.wikidata.org/wiki/Q424401","display_name":"Epidermal growth factor receptor","level":3,"score":0.5985503196716309},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.5617480278015137},{"id":"https://openalex.org/C2779251935","wikidata":"https://www.wikidata.org/wiki/Q5385089","display_name":"ErbB","level":3,"score":0.5443335175514221},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.5251736044883728},{"id":"https://openalex.org/C2777329042","wikidata":"https://www.wikidata.org/wiki/Q420323","display_name":"Lapatinib","level":5,"score":0.4978964328765869},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.4819888472557068},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.48143336176872253},{"id":"https://openalex.org/C42362537","wikidata":"https://www.wikidata.org/wiki/Q87099740","display_name":"Tyrosine kinase","level":3,"score":0.4787239730358124},{"id":"https://openalex.org/C101544691","wikidata":"https://www.wikidata.org/wiki/Q420511","display_name":"Receptor tyrosine kinase","level":3,"score":0.42774146795272827},{"id":"https://openalex.org/C170493617","wikidata":"https://www.wikidata.org/wiki/Q208467","display_name":"Receptor","level":2,"score":0.3322926461696625}],"mesh":[{"descriptor_ui":"D000818","descriptor_name":"Animals","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D000971","descriptor_name":"Antineoplastic Combined Chemotherapy Protocols","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D001943","descriptor_name":"Breast Neoplasms","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D001943","descriptor_name":"Breast Neoplasms","qualifier_ui":"Q000201","qualifier_name":"enzymology","is_major_topic":false},{"descriptor_ui":"D001943","descriptor_name":"Breast Neoplasms","qualifier_ui":"Q000235","qualifier_name":"genetics","is_major_topic":false},{"descriptor_ui":"D001943","descriptor_name":"Breast Neoplasms","qualifier_ui":"Q000401","qualifier_name":"mortality","is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D014408","descriptor_name":"Biomarkers, Tumor","qualifier_ui":"Q000037","qualifier_name":"antagonists & inhibitors","is_major_topic":true},{"descriptor_ui":"D014408","descriptor_name":"Biomarkers, Tumor","qualifier_ui":"Q000235","qualifier_name":"genetics","is_major_topic":false},{"descriptor_ui":"D014408","descriptor_name":"Biomarkers, Tumor","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D016896","descriptor_name":"Treatment Outcome","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D017451","descriptor_name":"Receptors, Somatomedin","qualifier_ui":"Q000037","qualifier_name":"antagonists & inhibitors","is_major_topic":false},{"descriptor_ui":"D017451","descriptor_name":"Receptors, Somatomedin","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D017526","descriptor_name":"Receptor, IGF Type 1","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D018719","descriptor_name":"Erb-b2 Receptor Tyrosine Kinases","qualifier_ui":"Q000037","qualifier_name":"antagonists & inhibitors","is_major_topic":true},{"descriptor_ui":"D018719","descriptor_name":"Erb-b2 Receptor Tyrosine Kinases","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D019008","descriptor_name":"Drug Resistance, Neoplasm","qualifier_ui":null,"qualifier_name":null,"is_major_topic":true},{"descriptor_ui":"D019061","descriptor_name":"src-Family Kinases","qualifier_ui":"Q000037","qualifier_name":"antagonists & inhibitors","is_major_topic":false},{"descriptor_ui":"D019061","descriptor_name":"src-Family Kinases","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D019859","descriptor_name":"Proto-Oncogene Proteins c-met","qualifier_ui":"Q000037","qualifier_name":"antagonists & inhibitors","is_major_topic":false},{"descriptor_ui":"D019859","descriptor_name":"Proto-Oncogene Proteins c-met","qualifier_ui":"Q000235","qualifier_name":"genetics","is_major_topic":false},{"descriptor_ui":"D019859","descriptor_name":"Proto-Oncogene Proteins c-met","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D047428","descriptor_name":"Protein Kinase Inhibitors","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D047428","descriptor_name":"Protein Kinase Inhibitors","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D058534","descriptor_name":"Class I Phosphatidylinositol 3-Kinases","qualifier_ui":"Q000235","qualifier_name":"genetics","is_major_topic":false},{"descriptor_ui":"D058570","descriptor_name":"TOR Serine-Threonine Kinases","qualifier_ui":"Q000037","qualifier_name":"antagonists & inhibitors","is_major_topic":false},{"descriptor_ui":"D058570","descriptor_name":"TOR Serine-Threonine Kinases","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D058990","descriptor_name":"Molecular Targeted Therapy","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":4,"locations":[{"id":"doi:10.18632/oncotarget.7043","doi":"https://doi.org/10.18632/oncotarget.7043","is_oa":true,"landing_page_url":"https://doi.org/10.18632/oncotarget.7043","pdf_url":"http://www.oncotarget.com/index.php?journal=oncotarget&page=article&op=download&path%5B%5D=7043&path%5B%5D=20010","source":{"id":"https://openalex.org/S126644158","display_name":"Oncotarget","issn_l":"1949-2553","issn":["1949-2553"],"is_oa":true,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","medline","poland-100","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310316297","host_organization_name":"Impact Journals LLC","host_organization_lineage":["https://openalex.org/P4310316297"],"host_organization_lineage_names":["Impact Journals LLC"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Oncotarget","raw_type":"journal-article"},{"id":"pmh:oai:europepmc.org:4211357","doi":null,"is_oa":true,"landing_page_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/5325455","pdf_url":null,"source":{"id":"https://openalex.org/S4306400806","display_name":"Europe PMC (PubMed Central)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1303153112","host_organization_name":"European Bioinformatics Institute","host_organization_lineage":["https://openalex.org/I1303153112"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":null,"raw_type":"Text"},{"id":"pmh:oai:pubmedcentral.nih.gov:5325455","doi":null,"is_oa":true,"landing_page_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/5325455","pdf_url":null,"source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Oncotarget","raw_type":"Text"},{"id":"pmid:26824988","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/26824988","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Oncotarget","raw_type":"Journal Article"}],"best_oa_location":{"id":"doi:10.18632/oncotarget.7043","doi":"https://doi.org/10.18632/oncotarget.7043","is_oa":true,"landing_page_url":"https://doi.org/10.18632/oncotarget.7043","pdf_url":"http://www.oncotarget.com/index.php?journal=oncotarget&page=article&op=download&path%5B%5D=7043&path%5B%5D=20010","source":{"id":"https://openalex.org/S126644158","display_name":"Oncotarget","issn_l":"1949-2553","issn":["1949-2553"],"is_oa":true,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","medline","poland-100","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310316297","host_organization_name":"Impact Journals LLC","host_organization_lineage":["https://openalex.org/P4310316297"],"host_organization_lineage_names":["Impact Journals LLC"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Oncotarget","raw_type":"journal-article"},"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":1.0}],"sustainable_development_goals_aurora":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":0.8600000143051147}],"study_designs":[],"awards":[{"id":"https://openalex.org/G9000878657","display_name":"Cancer Center Support Grant","funder_award_id":"P30CA016672","funder_id":"https://openalex.org/F4320337351","funder_display_name":"National Cancer Institute"}],"funders":[{"id":"https://openalex.org/F4320337351","display_name":"National Cancer Institute","ror":"https://ror.org/040gcmg81"}],"has_content":{"pdf":true,"grobid_xml":true},"content_urls":{"pdf":"https://content.openalex.org/works/W2284518511.pdf","grobid_xml":"https://content.openalex.org/works/W2284518511.grobid-xml"},"referenced_works_count":110,"referenced_works":["https://openalex.org/W346098014","https://openalex.org/W628007497","https://openalex.org/W767052336","https://openalex.org/W1601076886","https://openalex.org/W1748137726","https://openalex.org/W1761600715","https://openalex.org/W1847166854","https://openalex.org/W1867192432","https://openalex.org/W1925211454","https://openalex.org/W1973188134","https://openalex.org/W1975732704","https://openalex.org/W1979491122","https://openalex.org/W1985995844","https://openalex.org/W1996778928","https://openalex.org/W2001447115","https://openalex.org/W2005311581","https://openalex.org/W2010601523","https://openalex.org/W2012634952","https://openalex.org/W2015512041","https://openalex.org/W2015554240","https://openalex.org/W2020372547","https://openalex.org/W2023681515","https://openalex.org/W2027684043","https://openalex.org/W2029166421","https://openalex.org/W2033974104","https://openalex.org/W2036988959","https://openalex.org/W2043496241","https://openalex.org/W2052953726","https://openalex.org/W2053600405","https://openalex.org/W2054042846","https://openalex.org/W2055235037","https://openalex.org/W2057059975","https://openalex.org/W2059411043","https://openalex.org/W2062110561","https://openalex.org/W2066671159","https://openalex.org/W2068326740","https://openalex.org/W2069526613","https://openalex.org/W2083293423","https://openalex.org/W2086224272","https://openalex.org/W2096065464","https://openalex.org/W2096433824","https://openalex.org/W2096724429","https://openalex.org/W2097698108","https://openalex.org/W2098544382","https://openalex.org/W2099019742","https://openalex.org/W2100271152","https://openalex.org/W2101574075","https://openalex.org/W2101824720","https://openalex.org/W2103808574","https://openalex.org/W2104659222","https://openalex.org/W2104728809","https://openalex.org/W2107831804","https://openalex.org/W2110444464","https://openalex.org/W2110887292","https://openalex.org/W2111578514","https://openalex.org/W2112434826","https://openalex.org/W2112499354","https://openalex.org/W2114011767","https://openalex.org/W2114101532","https://openalex.org/W2114149997","https://openalex.org/W2115007832","https://openalex.org/W2116424772","https://openalex.org/W2117391818","https://openalex.org/W2118419063","https://openalex.org/W2120627364","https://openalex.org/W2120661754","https://openalex.org/W2120871937","https://openalex.org/W2120878737","https://openalex.org/W2121216406","https://openalex.org/W2126073113","https://openalex.org/W2127433418","https://openalex.org/W2127714324","https://openalex.org/W2129110050","https://openalex.org/W2132537022","https://openalex.org/W2133105825","https://openalex.org/W2136775492","https://openalex.org/W2137228442","https://openalex.org/W2138523530","https://openalex.org/W2140354367","https://openalex.org/W2140864342","https://openalex.org/W2141393790","https://openalex.org/W2144499620","https://openalex.org/W2145477245","https://openalex.org/W2148181778","https://openalex.org/W2148811436","https://openalex.org/W2153304468","https://openalex.org/W2158927987","https://openalex.org/W2159459001","https://openalex.org/W2159967578","https://openalex.org/W2162488896","https://openalex.org/W2162901058","https://openalex.org/W2166199281","https://openalex.org/W2167188058","https://openalex.org/W2169344919","https://openalex.org/W2169782526","https://openalex.org/W2169816570","https://openalex.org/W2172118845","https://openalex.org/W2172265576","https://openalex.org/W2220945839","https://openalex.org/W2240030606","https://openalex.org/W2253802753","https://openalex.org/W2262665695","https://openalex.org/W2281272171","https://openalex.org/W2286693725","https://openalex.org/W2318605753","https://openalex.org/W2513644020","https://openalex.org/W2560367415","https://openalex.org/W2597786088","https://openalex.org/W2617635878","https://openalex.org/W2915478882"],"related_works":["https://openalex.org/W129811225","https://openalex.org/W2167158887","https://openalex.org/W2024788439","https://openalex.org/W1980554079","https://openalex.org/W7009165784","https://openalex.org/W2727635070","https://openalex.org/W2032942530","https://openalex.org/W2207982014","https://openalex.org/W2156677665","https://openalex.org/W1997285329"],"abstract_inverted_index":{"//":[0,58],"Debora":[1,53],"de":[2,25,54],"Melo":[3,55],"Gagliato":[4],"1":[5,11,23,114],",":[6,12,336,338],"Denis":[7],"Leonardo":[8],"Fontes":[9],"Jardim":[10],"Mario":[13],"Sergio":[14],"Pereira":[15],"Marchesi":[16],"2":[17,32,135,146],"and":[18,123,161,179,223,236,269,285,326,356,440],"Gabriel":[19],"N.":[20],"Hortobagyi":[21],"3":[22,39,201],"Centro":[24],"Oncologia":[26],"do":[27],"Paran\u00e1,":[28],"Curitiba":[29],"SP,":[30,37],"Brazil":[31,38],"Roche":[33],"Pharmaceuticals,":[34],"S\u00e3o":[35],"Paulo":[36],"The":[40],"University":[41],"of":[42,107,129,142,156,175,207,231,245,256,266,273,276,332,347],"Texas":[43],"MD":[44],"Anderson":[45],"Cancer":[46,88],"Center,":[47],"Houston,":[48],"TX,":[49],"USA":[50],"Correspondence":[51],"to:":[52],"Gagliato,":[56],"email:":[57],"Keywords":[59],":":[60,72,77,82],"breast":[61,111,159],"cancer,":[62],"HER2":[63,203,225,304,333],"disease,":[64,379],"trastuzumab,":[65,321],"anti-HER2":[66,384,400,428],"therapy,":[67],"resistance":[68,426],"to":[69,154,191,239,293,425,427,436,447,454],"treatment":[70,313,401],"Received":[71],"September":[73],"08,":[74],"2015":[75],"Accepted":[76],"January":[78,83],"18,":[79],"2016":[80,85],"Published":[81],"27,":[84],"Abstract":[86],"Breast":[87],"(BC)":[89],"is":[90,117,149,204,237,263],"a":[91,103,205,274,361,396],"highly":[92],"prevalent":[93],"disease.":[94],"A":[95],"woman":[96],"living":[97],"in":[98,132,151,185,280,299,354,360,386,430,444],"the":[99,118,124,172,186,208,232,241,246,260,264,344,387,441,455],"United":[100],"States":[101],"has":[102],"12.3%":[104],"lifetime":[105],"risk":[106],"being":[108,294,381],"diagnosed":[109,301,349],"with":[110,229,302,314,350,383],"cancer":[112,122,130],"[":[113,134,200,252,288,334,364],"].":[115,136,202,254,290,368],"It":[116],"most":[119,126],"common":[120,127],"female":[121],"second":[125],"cause":[128],"death":[131],"women":[133,300,373],"Of":[137],"note,":[138],"amplification":[139],"or":[140,220,249],"overexpression":[141,305],"Human":[143],"Epidermal":[144],"Receptor":[145],"(HER2)":[147],"oncogene":[148],"present":[150],"approximately":[152],"18":[153],"20%":[155],"primary":[157],"invasive":[158],"cancers,":[160],"until":[162],"personalized":[163],"therapy":[164,385],"became":[165],"available":[166],"for":[167],"this":[168,438,449],"specific":[169],"BC":[170,188,198],"subtype,":[171],"worst":[173],"rates":[174],"Overall":[176],"Survival":[177,181],"(OS)":[178],"Recurrence-Free":[180],"(RFS)":[182],"were":[183],"observed":[184],"HER2+":[187,351],"cohort,":[189],"compared":[190],"all":[192],"other":[193,233,247],"types,":[194],"including":[195,406],"triple":[196],"negative":[197],"(TNBC)":[199],"member":[206],"epidermal":[209],"growth":[210],"factor":[211,298],"receptor":[212,267],"(EGFR)":[213],"family.":[214],"Other":[215],"family":[216],"members":[217],"include":[218],"EGFR":[219],"HER1,":[221],"HER3":[222],"HER4.":[224],"can":[226],"form":[227],"heterodimers":[228],"any":[230],"three":[234],"receptors,":[235],"considered":[238],"be":[240,452],"preferred":[242],"dimerization":[243,268],"partner":[244],"HER":[248],"ErbB":[250],"receptors":[251],"4":[253],"Phosphorylation":[255],"tyrosine":[257,329],"residues":[258],"within":[259],"cytoplasmic":[261],"domain":[262],"result":[265],"culminates":[270],"into":[271],"initiation":[272],"variety":[275],"signalling":[277],"pathways":[278,421],"involved":[279,443],"cellular":[281],"proliferation,":[282],"transcription,":[283],"motility":[284],"apoptosis":[286],"inhibition":[287],"5":[289],"In":[291],"addition":[292],"an":[295],"important":[296],"prognostic":[297],"BC,":[303,352,431],"also":[306],"identifies":[307],"those":[308],"patients":[309,348],"who":[310],"benefit":[311],"from":[312],"agents":[315],"that":[316,374,422],"target":[317],"HER2,":[318],"such":[319,410],"as":[320,411],"pertuzumab,":[322],"trastuzumab":[323,342],"emtansine":[324],"(T-DM1)":[325],"small":[327],"molecules":[328],"kinase":[330],"inhibitors":[331],"6":[335],"11":[337],"127":[339],"].In":[340],"fact,":[341],"altered":[343],"natural":[345],"history":[346],"both":[353],"early":[355,388],"metastatic":[357,378],"disease":[358,389,404],"setting,":[359],"major":[362,419],"way":[363],"8":[365],"-":[366],"10":[367],"Nevertheless,":[369],"there":[370],"are":[371],"many":[372],"will":[375,402,416,451],"eventually":[376],"develop":[377],"despite":[380],"treated":[382],"setting.":[390],"Moreover,":[391],"advanced":[392],"tumors":[393],"may":[394],"reach":[395],"point":[397],"where":[398],"no":[399],"achieve":[403],"control,":[405],"recently":[407],"approved":[408],"drugs,":[409],"T-DM1.":[412],"This":[413],"review":[414],"paper":[415],"concentrate":[417],"on":[418],"biological":[420],"ultimately":[423],"lead":[424],"therapies":[429],"summarizing":[432],"their":[433],"mechanisms.":[434],"Strategies":[435],"overcome":[437],"resistance,":[439],"rationale":[442],"each":[445],"tactics":[446],"revert":[448],"scenario":[450],"presented":[453],"reader.":[456]},"counts_by_year":[{"year":2026,"cited_by_count":5},{"year":2025,"cited_by_count":12},{"year":2024,"cited_by_count":9},{"year":2023,"cited_by_count":23},{"year":2022,"cited_by_count":20},{"year":2021,"cited_by_count":23},{"year":2020,"cited_by_count":23},{"year":2019,"cited_by_count":21},{"year":2018,"cited_by_count":19},{"year":2017,"cited_by_count":25},{"year":2016,"cited_by_count":17}],"updated_date":"2026-10-31T12:09:11.096373","created_date":"2016-06-24T00:00:00"}